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Abstract
Papillorenal syndrome (PRS, also known as renal-coloboma syndrome) is an autosomal dominant disease characterized by
potentially-blinding congenital optic nerve excavation and congenital kidney abnormalities. Many patients with PRS have
mutations in the paired box transcription factor gene, PAX2. Although most mutations in PAX2 are predicted to result in
complete loss of one allele’s function, three missense mutations have been reported, raising the possibility that more subtle
alterations in PAX2 function may be disease-causing. To date, the molecular behaviors of these mutations have not been
explored. We describe a novel mouse model of PRS due to a missense mutation in a highly-conserved threonine residue in
the paired domain of Pax2 (p.T74A) that recapitulates the ocular and kidney findings of patients. This mutation is in the Pax2
paired domain at the same location as two human missense mutations. We show that all three missense mutations disrupt
potentially critical hydrogen bonds in atomic models and result in reduced Pax2 transactivation, but do not affect nuclear
localization, steady state mRNA levels, or the ability of Pax2 to bind its DNA consensus sequence. Moreover, these mutations
show reduced steady-state levels of Pax2 protein in vitro and (for p.T74A) in vivo, likely by reducing protein stability. These
results suggest that hypomorphic alleles of PAX2/Pax2 can lead to significant disease in humans and mice.
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Introduction
Papillorenal syndrome (PRS, OMIM#120330, renal-coloboma
syndrome) is an autosomal dominant condition characterized by
congenital anomalies of the optic nerve and kidney [1–3]. Kidney
abnormalities range from aplasia or hypoplasia to cystic and
dysplastic changes [4–15]. These abnormalities, coupled with the
vesico-ureteral reflux observed in some patients, may lead to renal
failure [7,8,16,17]. Ocular abnormalities range from asymptom-
atic differences in retinal blood vessel patterning and optic nerve
pits to blinding congenital excavations of the optic nerve head [5].
Although the excavation and vascular abnormalities can be quite
subtle [10], other cases are reminiscent of the morning glory
anomaly or may be mistaken as normal-tension glaucoma.
Additional ocular features include the absence or hypoplasia of
the central retinal artery, foveal hypoplasia, and anomalous retinal
and choroidal perfusion leading to retinal thinning and visual field
deficits [7]. Some patients with PRS also have high frequency
hearing loss [2,4,6,10,17,18]. Schimmenti et al. have suggested that
Chiari 1 malformations and other CNS malformations may also
be an uncommon feature of this syndrome [17,19]. Germline
mosaicism has been reported [9].
Many patients with PRS have a mutation in the PAX2 gene, a
member of the paired box family of transcription factor genes
[4,6], that is normally expressed in the developing kidney, optic
cup, otic vesicle and midbrain-hindbrain boundary [20–23]. To
date, the vast majority of pathologic PAX2 mutations are predicted
to cause complete loss of function of one allele (haploinsufficiency)
[4–6,9,10,13,14,18,19]. The existing mouse models of PAX2
haploinsufficiency appropriately reflect the ocular, urogenital,
and otic abnormalities noted in human patients [22–26].
A few patients with PRS, however, have been reported to have
missense mutations, two of which cluster in the paired domain of
the protein [15,16]. The molecular mechanism by which these
mutations lead to disease has remained unexplored. We have
identified and characterized a novel mouse model of PRS in which
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in some humans with the disease. Furthermore, we have
characterized the molecular basis for this mouse mutation, as well
as for the paired domain missense mutations reported in humans.
We show that the mutant mice recapitulate the ocular and kidney
phenotypes of patients with PRS. We model the effect of these
mutations on Pax2 structure in silico and demonstrate that these
mutant proteins are expressed in vitro and in vivo at lower steady-
state levels than wild-type protein and that this leads to a
commensurate reduction in Pax2 transactivation and protein
stability in vitro. Furthermore, we observe that these mutations do
not appear to affect nuclear localization, the steady-state levels of
Pax2 mRNA or the ability of these proteins to bind a PAX2
consensus sequence in vitro. These combined results argue that
patients with these missense mutations in PAX2 likely develop PRS
because of the hypomorphic nature of these alleles and that their
residual function is not sufficient to prevent significant ocular and
renal disease.
Results
Identification of mouse mutant
During our ENU mutagenesis screen of C57BL/6 mice, we
discovered a line of mice that exhibited congenital excavation of
the optic nerve head and abnormal patterning of retinal blood
vessels (Figure 1). This excavation was confirmed on histologic
sections, which also show abnormalities in retinal lamination, such
as rosette formation. This phenotype was transmitted as an
autosomal dominant trait with complete penetrance on the native
C57BL/6 background. Mapping was performed by mating
affected C57BL/6 mice of either gender to C3H/HeJ mice to
produce G1 progeny. Affected mice were then backcrossed to
wild-type C57BL/6 mice. Assaying twelve of these affected G2
progeny for homozygosity of C57BL/6 markers revealed zero
recombinants at chromosome markers D19Mit120 and
D19Mit17.1. Of the 61 G1 animals and 122 G2 animals
ascertained, 10 animals (16%, 7 males, 3 females) and 31animals
(25%, 9 males, 22 females), respectively, met criteria for ‘‘affected’’
status; this finding suggests reduced penetrance for the optic nerve
phenotype on the C3H/HeJ genetic background.
The paired-box transcription factor gene, Pax2, was noted to be
within the critical interval on chromosome 19. Because mutation
of PAX2 in humans is known to result in congenital optic nerve
abnormalities, we considered it an excellent candidate gene.
Sequencing of the coding exons and the intron-exon boundaries of
Pax2 revealed a heterozygous c.A220G sequence change,
predicted to change threonine 74 to an alanine at the protein
level. This threonine is invariantly conserved in Pax2 across several
vertebrate species (human, mouse, chicken, frog, Medaka fish) and
in all murine members of the paired-box family (Pax1 through
Pax9) (Figure 2B and 2C).
Structural characterization of wild-type and mutant Pax2
proteins
To better understand the role this mutation may be playing in
Pax2 protein structure, we created an atomic model of the Pax2
paired domain-DNA hetero-complex (Figure 2A). Because the
modeling of Pax2 was performed using structural information
from the homeodomain of PAX6 as a guide, all interactions we
described should be considered predicted. The Pax2 paired
domain contains 2 similar globular protein sub-domains, known
as N (residues 16–74) and C (residues 88–148) subdomains, linked
by the extended 12-residue polypeptide chain (residues 75–87)
similar to that of PAX6 paired domain [27]. The Pax2 N-
subdomain includes an anti-parallel b-hairpin (residues 16–27) and
3 a-helices, a1 (residues 33–46), a2 (residues 49–57), and a3
(residues 58–74), folded like a homeodomain. The C-subdomain
also include 3 a-helices, a4 (residues 88–105), a5 (residues 109–
120) and a6 (residues 131–146), related by approximate 2-fold
symmetry to N-domain helices. Although the C-subdomain is
involved in protein-DNA interaction, the N-subdomain plays a
dominant role in DNA binding of the intact PAX6 paired domain
[27]. From a previous crystallographic study, it was suggested that
conserved residues at the end of a3-helix help to fix the position of
the extended linker by conservation of hydrogen bonds and
hydrophobic interactions [28]. In addition, the a3-helix, known as
a recognition helix, is a part of a helix-turn-helix (HTH) motif,
involving helices a2 and a3. All these data suggest that the
properties of the conserved sequence at the end of the a3-helix and
at the beginning of the polypeptide linker are important to
maintain the paired domain-DNA interactions.
In the mutant T74A, the polar threonine is replaced by
hydrophobic alanine residue breaking 2 hydrogen bonds (H-bonds
1 and 2 at corresponding distances 2.8 A ˚ and 3.1 A ˚) present in
wild type protein as shown in Figure 2D. In wild type protein these
H-bonds are connecting c-oxygen of threonine 74 to a backbone
oxygen of residue R70 (H-bond 1) and a main chain nitrogen of
serine 76 (H-bond 2). Missense mutation T74A disrupts both
bonds (Figure 2D). Although Pax2 is known to be phosphorylated
by kinases such the c-Jun N-terminal kinase (JNK) [29,30], in silico
analysis of the Pax2 protein sequence using two different programs
(http://www.cbs.dtu.dk/services/NetPhos/ and http://scansite.
mit.edu/motifscan_seq.phtml) predicted that threonine 74 is not
a likely site for phosphorylation.
Characterization of mouse mutant
Congenital optic nerve excavation co-segregated with the
Pax2
A220G allele 100% of the time in over 100 mice analyzed,
indicating complete penetrance for this phenotype on the C57BL/
6 background. Of 31 offspring of a Pax2
A220G/+ x Pax2
A220G/+
mating, 22 (71%) were affected, Pax2
A220G/+ and 9 (29%) were
unaffected, Pax2
+/+.N oPax2
A220G/A220G mice were observed,
which statistically deviates from the expected ratios of 1:2:1
homozygotes to heterozygotes to wild-type mice (p,0.01). In
Author Summary
Congenital ocular malformations affecting the optic nerve
are an important cause of childhood blindness. The
papillorenal syndrome (PRS) is an autosomal dominant
disorder that causes congenital optic nerve and kidney
abnormalities, which may result in legal blindness and
renal failure, respectively. Many cases of PRS are caused by
mutations in the paired-box transcription factor PAX2.I n
this paper, we describe a novel mouse model of this
human disease caused by a missense mutation in the Pax2
gene at the same position of one of the few disease-
causing missense mutations in humans. We characterize
the ocular and non-ocular phenotypes of this mouse and
model the effect that murine and human Pax2/PAX2
mutations have on protein structure. We also experimen-
tally test the effect these missense mutations have on
protein localization, transactivation, and DNA binding,
concluding that all three reduce steady-state levels of
protein in vitro and (in p.T74A) in vivo by reducing protein
stability. This work will help us better understand the
pathophysiology of PRS and to dissect the molecular
interactions important in normal PAX2 function.
PAX2 Missense Mutations
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matings revealed 7 (20%) homozygotes, which is not significantly
different from the expected ratio. These observations suggest that
homozygosity for the Pax2
A220G allele is lethal either later in
gestation or perinatally. We have observed some Pax2
A220G/A220G
embryos, however, as late as E17.5 (n=45).
Because Pax2 null alleles had previously been reported to affect
ocular, urogenital, and central nervous system development
[22–25,31], we examined these features pre- and postnatally in
our mouse mutants. During ocular development in wild-type
embryos, the edges of the optic fissure touch at E11.5 and fuse
by E12.5 (Figure 3A and 3E). The invading mesenchyme has
coalesced into a discernible central vascular trunk (the tunica
vasculosis lentis) by E13.5 (Figure 3C). In contrast, Pax2
A220G/A220G
embryos have delayed optic fissure closure (Figure 3B), which
sometimes results in frank uveal coloboma (Figure 3F). The
differentiation of neural crest into discernible vascular structures is
also delayed (Figure 3D). In addition to congenital optic nerve
excavation, adult Pax2
A220G/+ mice exhibited variable, incomplete
regression of the tunica vasculosis lentis, retinal dysplasia, bending
of the retinal vasculature towards the dorsal retina, absence of a
central retinal arterial trunk, and mild extension of the retinal
pigment epithelium beyond the borders of the optic disc
(Figure 1D, 1E, and 1G, and data not shown).
The developing kidneys of wild-type mice show induction of
surrounding mesenchyme to form early glomeruli and tubules by
E13.5 and have well differentiated cortical and medullary
structures by E17.5 (Figure 4A). The kidneys of Pax2
A220G/A220G
Figure 1. Clinical ocular phenotype in C57BL/6-Pax2
+/A220G mice compared to wild-type, C57BL/6 mice. (A) Fundus photograph of
C57BL/6 mouse showing normal optic nerve and radial pattern of retinal blood vessels. (B) Fundus photograph of C57BL/6-Pax2
+/A220G mouse
showing congenital excavation of the optic nerve head with peripapillary pigment changes (arrow). (C) Lectin immunofluorescence of wild-type
C57BL/6 mouse showing normal, radial vessel patterning. (D,E) Lectin immunofluorescence of C57BL/6-Pax2
+/A220G mice showing abnormal vascular
patterning, including curving of vessels towards the dorsal retina (D, arrows, d=dorsal, v=ventral) and separation of the central retinal vascular
trunks (E, arrows). Histologic section of a Pax2
+/+ (F) and a Pax2
+/A220G (G) mouse eye through the optic nerve and peripapillary retina showing
abnormal excavation of the optic nerve (G, arrow) and retinal rosette formation (G, arrowhead). Remnants of the tunica vasculosis lentis and mild
extension of the retinal pigment epithelium were variably noted in histopathology from other Pax2
A220G/+ eyes (data not shown).
doi:10.1371/journal.pgen.1000870.g001
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chyme by E13.5, resulting in small, primordial kidneys at E17.5
(Figure 4B). Of the sixteen Pax2
A220G/+ mice (ages 1-4 months)
analyzed with gross and microscopic pathology, 1/16 had bilateral
cystic kidneys with hydronephrosis and hydroureter; 1/16 had
unilateral renal hypoplasia with contralateral double papilla; 1/16
had unilateral renal hypoplasia with occasional focal cystic
glomeruli; and 7 mice had bilateral, rare to occasional degener-
ative tubules on histologic sectioning. Of the seven age-matched,
wild-type mice (14 kidneys) similarly examined, only one kidney
had rare degenerative tubules on histologic sectioning.
In contrast to other Pax2 mouse mutants [23,24], the midbrain-
hindbrain boundary of Pax2
A220G/A220G develops relatively nor-
mally, as assessed by cerebellar development at E17.5 (n=11
Pax2
A220G/A220G,n = 1 2Pax2
+/A220G ) (Figure 4C and 4D). In
embryos E10.5 to E12.5, 3/38 (8%) heterozygotes and 5/36 (14%)
homozygotes had a mildly-flattened midbrain-hindbrain region,
but otherwise normal isthmic structures. Cranial shape in
homozygous mutant was grossly normal at E14.5 (Figure 4E and
4F) and at E17.5 (data not shown). We did not observe
exencephaly, as has been previously reported (n=45 wild-type,
n=45 heterozygote mutants, and n=45 homozygotes) [23,24].
Gross examination of the optic chiasm in homozygous mice
showed no discernable abnormality (n=45).
Functional characterization of Pax2 missense mutations
During our investigations, we noted that the predicted T74A
mutation in mouse Pax2 (which corresponds to T75 in the human
protein), was next to or in the same location as two of the three
missense mutations reported in humans—c.G226A (p.G76S) and
c.220insGAGACC (p.74dupET) [15]. These mutations corre-
spond to c.G223A (p.G75S) and c.222insGAGACC (p.73dupET),
respectively, in the mouse sequence. For clarity, we will refer to
these mutations using the mouse sequence, as this is the sequence
that was experimentally tested.
As in the c.A220G (p.T74A) mutant, atomic modeling of the
c.G223A (p.G75S) mutation shows that the hydrogen bond
between nitrogen atom of glycine 75 and oxygen atom of tyrosine
71 located at 2.9 A ˚ distance in the wild type Pax2 paired domain is
broken (H-bond 3, Figure 2F). Both these mutations are affecting
the conserved intramolecular interactions at the end of helix a3
and potentially could destabilize this local structure. In the
c.222insGAGACC (p.dup73ET) mutation, the insertion of
additional glutamic acid and threonine after amino acid 74
changes the local structure at the end of helix 3 and the beginning
of the inter-domain linker (Figure 2E). This change causes a
decrease in the secondary structure of the a3-helix and might
introduce a conformational change in the inter-domain linker that
could result in the loss of protein binding specificity.
Figure 2. Homology modeling of the wild-type and mutant Pax2 paired domain-DNA complex. The paired domain of wild-type Pax2
domain DNA are represented by red and white ribbons, respectively, and their corresponding atomic structures are shown by red and white bonds
(A). Hydrogen bonds are shown in blue. Threonine 74 in the mouse protein sequence (equivalent to T75A in human) is absolutely conserved across
several species (B) and across all known murine Pax-family members (C). Fragments of the Pax2 paired domain–DNA complex modified by the
mutations T74A, dup73ET and G75S are shown on (D–F), respectively. Hydrogen bonds presented in the wild type protein that are broken by the
mutation T74A are labeled as 1 and 2 for (D) and by the mutation G75S is labeled as 3 (F). Yellow arrows indicate the location of mutations in Pax2
paired domain. A schematic of the Pax2b protein modified from Lechner et al. [32] showing the paired domain (gray), the octapeptide (Oct) domain
(yellow), and the C-terminus, which is rich in proline, serine, threonine and tyrosine (PSTY) residues (G). Numbers indicate amino acid position. The
arrow denotes the approximate position of the three mutations studied.
doi:10.1371/journal.pgen.1000870.g002
PAX2 Missense Mutations
PLoS Genetics | www.plosgenetics.org 4 March 2010 | Volume 6 | Issue 3 | e1000870In order to directly assay the effect these three missense
mutations have on Pax2 function, we expressed them in a mouse
fibroblast cell line (NIH/3T3) and compared their ability to drive
expression of a Pax2-responsive reporter gene [32,33]. All three
mutant proteins showed an approximately 50% reduction in their
ability to transactivate this reporter gene (Figure 5A). Reduced
transactivation could be due to one or more of the following
reasons: 1) reduced steady-state levels of Pax2 mRNA, resulting in
less Pax2 protein; 2) reduced stability of the abnormal Pax2
protein; 3) failure of the mutant Pax2 proteins to localize to the
nucleus; and/or 4) failure of the protein to bind to DNA and
transactivate target genes. In our cell culture model, all three
mutant Pax2 proteins showed a considerable decrease in steady-
state levels of protein expression when compared to wild-type
protein (Figure 5B). Semi-quantitative image analysis of Pax2 band
intensity demonstrated steady-state levels of 35% (Pax2
A220G), 32%
(Pax2
G223A), and 38% (Pax2
222insGAGACC) that of wild-type Pax2,
when corrected for steady-state levels of Gapdh expression.
Similar results were observed when the experiments were
performed in COS-7 cells (data not shown). Steady-state levels
of Pax2 mRNA are similar in both wild-type and mutant construct-
transfected cells (Figure 6A, Table 1), suggesting that our
observations are mediated at the level of the Pax2 protein. In
fact, the mutant Pax2 protein products are considerably less stable
in vitro–as measured by a time-dependent decrease in Pax2
expression in cycloheximide-treated cells—than the wild-type
protein (Figure 6B and 6C).
In support of this in vitro observation, the magnitude of Pax2
immunofluorescence was qualitatively reduced in the optic stalk of
Pax2
A220G/A220G E11.5 mouse embryos when compared to
Figure 3. Histologic sections of Pax2
+/+ and Pax2
A220G/A220G mouse eyes at three embryonic time points. At E11.5, parasagittal sections
reveal a delay in apposition of the edges of the optic fissure in mutant mice (arrow) (A,B). At E13.5, coronal sections through the wild-type and
homozygous mutant embryos reveal a delay in the formation of the tunica vasculosis lentis (arrow) (C,D). At E17.5, parasagittal sections demonstrate
non-fusion of the optic fissure (uveal coloboma) in mutant embryos (arrow) (E,F). V=ventral retina.
doi:10.1371/journal.pgen.1000870.g003
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expression pattern of Pax2 was, however, quite similar, making a
gross patterning defect in the developing mouse eye less likely.)
When relative levels of Pax2 expression were compared in head
tissue from E11.5 mouse embryos by Western blot, a similar
pattern was observed (Figure 7B). Semi-quantitative image analysis
of Western blot band intensity demonstrated steady state levels of
54% and 13% in heterozygous and homozygous Pax2 mutants,
respectively, when compared to wild-type embryos, after corrected
for Gapdh expression. Pax2 immunofluorescence on transfected
COS cells demonstrated that wild-type and each of the three
mutant proteins were uniformly, correctly targeted to the nucleus
(Figure 8). As previously noted, this region of the Pax2 protein is
not predicted to contact DNA and we therefore predicted that its
ability to bind a Pax2 consensus sequence would not be drastically
altered. In support of this in silico observation, electrophoretic
mobility shift assays of the wild-type and mutant proteins showed
no significant difference in their ability to bind a paired box
consensus DNA sequence (Figure 9) at a concentration shown to
be optimal for the wild-type protein. Taken together, these data
suggest that the major pathophysiologic mechanism of these three
missense mutations is to reduce the stability of Pax2/PAX2
protein and not to affect the steady state levels of Pax2 mRNA,
Pax2 protein localization or the ability of the protein to bind its
DNA recognition sequence.
Discussion
Although most mutations that cause PRS are predicted to cause
complete loss-of-function of one PAX2 allele, a few missense
mutations clustering in the paired-box domain of the protein have
been reported. This observation raises the possibility that a
partially-functional or abnormally-functional protein product is
made in vivo. We have identified a novel missense mutation in the
mouse Pax2 gene that is in the same position as one of the few
human missense mutations.
Several lines of evidence suggest that this sequence change is
pathological. This mutation absolutely co-segregates with an
ocular and kidney phenotype reminiscent of human disease and
of previously-reported mouse models of PRS [22–25]. The
threonine residue affected by this mutation is absolutely conserved
in all members of the paired-box family of transcription factors in
Figure 4. Histologic sections of Pax2
+/+ and Pax2
A220G/A220G mouse kidneys (axial) and cerebellum (sagittal) at E17.5. Whereas wild-type
mice have begun to develop renal glomeruli (arrow, A) and tubules (arrowhead, A), the mutant mice have only primordial kidneys with poor
differentiation of these structures (arrow, B) In contrast, the differentiation of the cerebellum of both wild-type (C) and mutant (D) mice is comparable
at this time, despite the midbrain-hindbrain boundary being a site of Pax2 expression during embryogenesis. By E14.5, cranial structure was grossly
normal in both wild-type (E) and homozygous mutant (F) embryos.
doi:10.1371/journal.pgen.1000870.g004
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across several species. Mutation at this residue has been described
in individuals with PRS [15]. Furthermore, mutation of the
corresponding threonine (T63P) in the human PAX6 gene results
in a relatively mild form of aniridia characterized by subtle iris
hypoplasia, cataract and keratopathy along with nystagmus [34].
Lastly, our atomic modeling and in vitro functional studies suggest
that this murine mutation, as well as the other human PAX2
mutations reported in this region, mildly disrupt normal protein
structure and result in hypomorphic alleles.
The mechanism by which Pax2/PAX2 function is reduced in the
three mutations tested is a reduced level of steady-state Pax2/
PAX2 protein, likely due to a decrease in protein stability. Based
on crystallographic evidence, this residue is not anticipated to
contact DNA and electrophoretic mobility shift assays show no
difference between the three mutant and wild-type proteins. These
mutations do not affect the normal nuclear localization of the Pax2
protein in vitro. The protein is made in vivo, albeit at reduced levels.
The reduction in transactivation observed in vitro approximates the
reduction in steady-state protein levels in vitro or in vivo (for the
c.A220G mutant mice). Reduced steady-state levels of protein
have been proposed as a disease mechanism in other develop-
mental eye diseases caused by mutations in transcription factor
genes such as FOXC1 and PITX2 in Axenfeld-Rieger syndrome
[35–37]. Interestingly, increased steady-state levels of another
transcription factor protein, PAX6, are also thought to result in
developmental eye disease (e.g., ‘‘partial aniridia’’) [38], implying
that perturbation of steady-state protein levels in either direction
may cause disease. The relatively mild ocular presentation of the
patients with missense mutations in this region of the PAX2
protein is also consistent with our finding that the three alleles
tested are hypomorphic, rather than a complete loss-of-function
Figure 5. Comparison of wild-type and mutant Pax2 protein
transactivation and expression in cell culture. NIH/3T3 cells were
transfected with expression constructs for wild-type or mutant Pax2
along with a Pax2-responsive luciferase reporter gene. All three mutants
tested show reduced ability to transactivate (A). When steady-state
levels of Pax2 protein were compared on Western blots from these
experiments, mutants showed consistently lower levels of expression
(B). Similar findings were observed when these experiments were
replicated in COS-7 cells (data not shown).
doi:10.1371/journal.pgen.1000870.g005
Figure 6. Comparison of Pax2 mRNA steady-state levels and
Pax2 protein stability in wild-type and mutant expression
vector-transfected NIH/3T3 cells. Although steady-state levels of
Pax2 mRNA were comparable in wild-type and mutant transfected cells
(A), the short-term protein stability of mutant Pax2 protein products
were considerably reduced compared to wild-type, as determined in
cycloheximide translation-inhibition experiments (B,C). See also Table 1
for quantification of mRNA levels.
doi:10.1371/journal.pgen.1000870.g006
PAX2 Missense Mutations
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missense mutations—which are translated into protein in vitro and
in vivo—may also be affected Pax2/PAX2 interactions with other
proteins in the transcriptional complex and that these abnormal
protein-protein interactions are contributing to the pathogenesis of
disease.
Our mouse model of PRS shares many phenotypic similarities
to the two reported Pax2 mutant models [22–24] and to the Krd
mouse, which carries a large deletion on chromosome 19 that
includes Pax2 [25]. Similar to heterozygous, targeted Pax2 knock-
out mouse and the Pax2
1Neu mouse [23,24], Pax2
A220G/+ mice
exhibit congenital excavation of the optic nerve head with
extension of the retinal pigment epithelium beyond the optic disc.
Although minor defects in retinal lamination similar to those
described in the Krd mouse were noted in our model [25], we did
not observe the gross thinning of the retina observed in the Krd
mouse and the Pax2
1Neu mouse. This difference may be
attributable to the hypomorphic nature of our mutation,
differences in background strain (e.g., the presence of a partial
C3H background, which carries a mutation in phosphodiesterase
that results in retinal degeneration [39]) and/or–in the case of the
Krd mouse–the deletion of other genes in this region [40]. Unlike
the directed knockout and the Pax2
1Neu mouse [23,24], we did not
observe exencephaly or under-development of the midbrain-
hindbrain region, as measured by cerebellar size and morphology.
This difference may be due to the hypomorphic nature of our Pax2
allele and/or differences in the background strain of mouse used.
In fact, while Torres, et al. observed 11/59 exencephalic embryos
on a mixed 129sv x NMRI background, they did not observe
exencephaly in 14 homozygous knockout mice an inbred 129sv
background [23]. The mild kidney phenotype seen in Pax2
A220G/+
mice and the severe phenotype observed in Pax2
A220G/A220G mice
are similar to those described in all three mouse models
[22,24–26]. Porteous and colleagues have previously shown that
the renal hypoplasia seen in heterozygous Pax2 mutant mice is likely
due to increased apoptosis during fetal renal development [26].
The vascular patterning abnormalities that we observe in the
Pax2
A220G/+ mice are notable, as they recapitulate the phenotype
observed in patients with PRS, particularly the absence of a
central retinal artery [7]. PAX2 is expressed in human astrocyte
precursor cells and retinal astrocytes [41], which guide developing
angioblasts during retinal vascular development [42]. Chu et al.
have noted particularly strong Pax2 expression in astrocytes
surrounding the optic nerve head, and suggest that the congenital
optic nerve abnormalities noted in patients with PRS may be due
to a deficiency of astrocytes [43]. Therefore both the congenital
optic nerve excavation and the patterning abnormalities noted in
the Pax2
A220G/+ mice may be due to a primary defect in astrocyte
development and/or differentiation.
Threonine—the amino acid altered in the Pax2
A220G/+ mice—is
a potential target for protein kinases. Phosphorylation of Pax2 by
kinases such as the c-Jun N-terminal kinases (JNK) JNK-1 and
JNK-2 enhances its ability to activate transcription [29,30]. While
most of this phosphorylation occurs in the serine/threonine-rich
carboxyl terminus of the Pax2 protein, it is still possible that
phosphorylation of the paired domain may regulate Pax2
transcriptional activity. However, our in silico analysis and our
Western blot data do not suggest that threonine 74 (75 in humans)
is a likely site of phosphorylation in vitro or in vivo.
Pax2, like all transcription factors, likely acts as part of a multi-
protein complex to regulate transcription. For example, Gong et al.
found that Pax2 forms a complex with Hox11 paralogous proteins
and Eya1 and directly activates expression of Six2 and Gdnf in the
developing kidney [44]. While direct knock-out or nonsense
mutation of Pax2 presumably abrogates all such interactions, the
missense mutation of a well-conserved amino acid that results in
an expressed protein provides the opportunity to ask more specific
questions about how this area of Pax2 interacts with other
proteins. We feel that our mouse model will enable us to begin to
dissect physiologic Pax2 protein interactions and to help us better
understand how disruption of such interactions leads to human
disease.
Materials and Methods
Animal husbandry and clinical examination
C3H/HeJ (Stock # 000659) and C57BL/6J mice (Stock
#000664) were obtained from The Jackson Laboratory (Bar
Figure 7. Comparison of wild-type and mutant Pax2 expression
in embryonic mouse tissue. Pax2 immunofluorescence on parasag-
ittal sections of E11.5 wild-type and homozygous mutant embryos
demonstrate a normal pattern of expression in the ventral optic stalk
(A). The level of Pax2 expression, however, is qualitatively reduced in
the mutant mice. This reduced steady-state level of expression was
confirmed by Western blot in heterozygous and homozygous mutant
embryos (B).
doi:10.1371/journal.pgen.1000870.g007
Table 1. Threshold cycle (Ct) quantification of real-time,
reverse-transcriptase PCR of wild-type and mutant Pax2
transfected NIH/3T3 cells shows no significant difference in
steady-state levels of Pax2 mRNA relative to Gapdh.
Expression Vector Pax2 (Ct) Gapdh (Ct)
Mock - 17.7
WT 26.1 15.7
A220G 23.9 15.0
G223A 23.9 15.2
222insGAGACC 23.3 15.5
doi:10.1371/journal.pgen.1000870.t001
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Animal Review Board standards with a 14 hour light/10 hour
dark cycle. These studies conformed to the principles for
laboratory animal research outlined by the Animal Welfare Act
(NIH/DHHS) and the ARVO Statement for the Use of Animals
in Ophthalmic and Vision Research and were approved by the
Institutional Animal Care and Use Committee of the University of
California, Berkeley and the National Eye Institute. Ehtylnitro-
sourea (ENU) mutagenesis and breeding of mice were performed
as previously described[45]. Briefly, male C57BL/6 mice were
intraperitoneally injected with ENU (90 mg/kg body weight)
weekly three times. Three months after the injection, each mouse
was bred to wild-type C57BL/6J female mice to produce G1 mice,
which were screened for dominant eye phenotypes. Clinical
examination of the posterior segment was performed on gently
restrained, awake mice after dilation with one drop of 1%
tropicamide (Alcon Laboratories, Inc., Fort Worth, TX) using an
indirect ophthalmoscope (Keeler, Windsor, Berkshire, UK) with a
90D condensing lens (Volk, Mentor, OH). The optic nerve
phenotype was graded in each eye as follows: 0=normal,
+1=mildly affected (anomalous nerve with peripapillary pigment
changes), +2=strongly affected (findings of ‘‘+1’’ and staphylo-
matous changes), or indeterminate. A mouse was deemed
‘‘affected’’ if it had a score of two or more for both eyes combined
(i.e., at least a +1 score in each of both eyes or a +2 in one eye.)
Mice were euthanized with carbon dioxide according to
institutional guidelines. Enucleated adult mouse eyes were fixed
in a phosphate-buffered paraformaldehyde-glutaraldehyde mix-
ture according to published protocols [46]. Mouse embryos for
histopathology were dissected on ice-cold phosphate buffered
saline (PBS) and fixed overnight in phosphate-buffered 4%
paraformaldehyde at 4uC. Hematoxylin and eosin-stained meth-
acrylate sections via the pupillary-optic nerve axis (eyes) or in
appropriate cross section (embryos) were used for histopathology.
Genetic mapping
Microsatellite markers known to be informative for the two
strains were chosen from the Mouse Mapping Primers v1.0
(Applied Biosystems, Foster City, CA). PCR conditions were as
follows: 12 min denaturation at 95uC; 10 cycles of 94uC for 45 sec,
55uC for 1 min, and 72uC for 1 min; 20 cycles of 89uC for 1 min,
55uC for 1 min, and 72uC for 1 min; 10 min final extension at
72uC. The PCR products were pooled based on fluorescent labels
and expected allele size. Fragment separation was achieved by
capillary electrophoresis on a Genetic Analyzer 3100 using 36 cm
capillary array and POP-4 polymer. The ROX400 size standard
(Applied Biosystems, Foster City, CA) was run as an internal size-
standard. Allele sizing was calculated using the local southern
Figure 8. Pax2 immunofluoresence on COS-7 cells transfected with wild-type or mutant Pax2 expression vectors. Both wild-type and
mutant proteins display nuclear localization, as evidenced by co-localization of green fluorescence (Pax2) with DAPI nuclear staining (blue).
doi:10.1371/journal.pgen.1000870.g008
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(Applied Biosystems). Allele calling and binning was done using
the GENOTYPER software (Applied Biosystems). All genotyping
included control DNA from C57BL/6J strain, C3H/HeN strain
and C57BL/6J x C3H/HeN.
Modeling of PAX2 protein structure
The structure of wild-type Pax2 paired domain-DNA hetero-
complex was modeled using the PAX6 paired domain-DNA
complex structure (PDB: 6pax) from the RCSB database http://
www.rcsb.org/pdb as the structural template [47]. Primary
sequences of Pax2/PAX2 and Pax6/PAX6 from mice and human
were aligned by the method of Needleman & Wunsch [48], and
incorporated in the program Look, version 3.5.2 for 3-dimensional
structure prediction [49,50]. The wild-type Pax2 paired domain-
DNA hetero-complex and mutation dup74ET were built by the
automatic segment matching method in the program Look
followed by 500 cycles of energy minimization [51]. The same
program generated the conformation of the proteins with the
T74A and G76S mutations; and refined them by self-consistent
ensemble optimization (500 cycles) [50]. The geometry of the
predicted structures was tested with the program Procheck [52].
Immunofluorescence in cultured cells and mouse
embryos
Mouse embryos were dissected in PBS and fixed overnight in
4% paraformaldehyde in PBS followed by cryopreservation in
30% sucrose overnight at 4uC. Whole embryos were embedded
and frozen on dry ice in Neg –50 (Richard-Allan Scientific,
Kalamazoo, MI). 10 mM frozen sections were cut through mouse
eyes and slides were stored at 280uC. Tissue sections were then
thawed and washed three times in PBS, and then treated with 1X
target retrieval solution (pH 6) (Dako, Carpenteria, CA). After
washing three times in PBS, the section was incubated in blocking
reagent (10% normal donkey serum, 0.02% Triton X-100 in PBS)
for 1 hr. at room temperature. Slides were incubated overnight in
anti-murine Pax2 (1:1000, Covance, Berkeley, CA) at 4uC.
Following removal of primary antibody slides were washed four
times in PBS for ten minutes each and the Pax2 antibody was
detected using Donkey anti-rabbit Alexa Fluor 594 secondary
antibody (1:400, Molecular Probes Inc., Eugene, OR) for one hour
at room temperature. Slides were then washed again in PBS and
cover-slipped with Vectashield with DAPI (Vector Laboratories,
Burlingame, CA). At least 100 cells were counted for each
transfection.
For cell culture, COS-7 cells (ATCC, Manassas, VA) were
cultured on slides and fixed in 4% paraformaldehyde at room
temperature for 10 minutes, rinsed twice with wash buffer (0.1%
Tween 20, 0.5% normal goat serum in PBS) then cryoprotected by
incubation in 15% and 30% sucrose for 45 minutes each and
stored at 280uC. When ready for use, slides were thawed, washed
three times in PBS and incubated in blocking reagent (10%
normal goat serum, 0.1% Tween 20 in PBS) for 30 min. at room
temperature. Slides were incubated overnight in anti-murine Pax2
(1:200, Zymed, Carlsbad, CA) at 4uC. Following removal of
primary antibody slides were washed four times in PBS for five
minutes each and the Pax2 antibody was detected using goat anti-
rabbit Alexa Fluor 488 secondary antibody (1:1000, Molecular
Probes Inc., Eugene, OR) for one hour at room temperature.
Slides were then washed again in PBS and cover-slipped with
ProLong Gold with DAPI (Molecular Probes).
Fluorescence and brightfield images were taken with a Zeiss
AxioVert 200 microscope with a digital camera connected to a PC
running AxioVision 4.6.3 (Carl Zeiss MicroImaging, Thornwood,
NY). When making qualitative comparisons of the intensity of
immunofluorescence, care was taken to standardize exposure
times.
Lectin staining of retinal vasculature
Enucleated mice eyes were fixed in 4% paraformaldehyde in
PBS at room temperature for 30 minutes. After washing in PBS,
retinas were dissected and isolated. Four radial incisions were then
made in preparation for flat mount. Subsequently, retinas were
permeabilized and blocked in a solution of 0.5% Triton X100 and
Figure 9. Electrophoretic mobility shift assay comparing DNA binding of wild-type and three mutant Pax2 proteins. A labeled Pax2
DNA-binding consensus sequence was incubated in the presence or absence of nuclear extract of COS-7 cells expressing equal amounts of the wild-
type or mutant Pax2 protein; the same, unlabeled, competing DNA oligonucleotide; and/or a mutated version of the unlabeled oligonucleotide (Mut-
Pax2). Nuclear extracts from mock transfected cells did not appreciably result in a shift of the labeled Pax2 DNA-binding site oligonucleotide, whereas
wild-type and all three mutant Pax2 proteins bound the oligonucleotide with approximately equal affinity. Specificity for this binding was shown by
competing the binding with the same, unlabeled oligonucleotide sequence and by failure of an unlabeled mutant oligonucleotide to compete for
binding.
doi:10.1371/journal.pgen.1000870.g009
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1 hour. After PBS wash, retinas were incubated in TRITC-
conjugated lectin (1:100 dilution in PBS) overnight at 4uC. After
rinsing, retinas were flat mounted with slow-fade medium (Pro-
Long Gold, Invitrogen, Carlsbad, CA) and visualized under
microscopy with a TRITC filter.
Transactivation studies
PCR-based site directed mutagenesis of the CMV-Pax2b
expression construct [32,33] was performed according to
standard protocol to introduce one of the following mutations:
c.A220G, c.G223A, or c.222insGAGACC. These mutations in
the mouse sequence correspond to c.A223G (p.T75A), c.G226A
(p.G76S), and c.220insGAGACC (p.dup74ET) in the human
sequence, respectively. Mutations were confirmed by direct
sequencing. NIH/3T3 (mouse embryonic fibroblast) or COS-7
(African green monkey kidney) cells (ATCC, Manassas, VA) were
plated at 0.25610
6 cells per well in a 6-well plate in DMEM
media with 10% fetal bovine serum. The following day, cells were
transiently transfected with 0.5 micrograms of PRS4-luciferase
reporter construct [32,33], 50 nanograms of Renilla luciferase
construct (pRL-CMV, Promega, Inc., Madison, WI) and 2
micrograms of CMV-Pax2b expression construct (wild-type or
mutant) [30] using 10 ml/well lipofectamine 2000 (Invitrogen,
Carlsbad, CA) according to the manufacturer’s protocol. Control
samples were transfected with an equimolar amount of the
expression vector backbone. After 48 hours, cells were harvested
and luciferase activity was measured using microplate reader
(Optima, BMG labtech, Durham, NC). All experiments were
repeated at least three times with at least three replicates per
sample.
Western blotting
Transfected cells were harvested for protein in 1x Passive Lysis
Buffer. Total protein was determined using Micro-Lowry method
(Sigma-Aldrich, St. Louis, MO). Equal amounts of protein were
separated (4–12% NuPAGE Bis-Tris) polyacrylamide gels and
transferred to 0.2 mm, PVDF membranes (Invitrogen, Carlsbad,
CA). Blots were hybridized with 1:1000 dilution Rabbit anti-Pax2
antibody (Zymed, San Francisco, CA) and 1:4000 dilution of goat
anti-rabbit-HRP secondary antibody (Thermo Fischer Scientific,
Pierce Protein Research Products, Rockford, IL) and then
developed with SuperSignal West Pico chemiluminescent sub-
strate for detection of HRP (Thermo Fischer Scientific,
PierceProtein Research Products, Rockford, IL). Quantitation
was performed on a ChemiDoc EQ (Bio-Rad Laboratories,
Hercules, CA) using the manufacturer’s software (Quantity One,
v.4.5.2, Build 070).
Quantification of wild-type and mutant Pax2 mRNA
levels
NIH/3T3 cells were transiently transfected with wild type or
mutant Pax2 plasmids using FuGene 6 HD reagent (Roche-
Applied Science, Indianapolis, IN). 48 hrs. post transfection, RNA
was isolated using an RNeasy mini kit from Qiagen. 1 mg of RNA
was treated with DNase I to remove any DNA contamination
from the samples. cDNA was prepared using High Capacity
cDNA Reverse Transcription kit (Applied Biosystems, Foster City,
CA). Real time PCR was performed with SYBR green master mix
(Applied Biosystems) on Bio-Rad iCycler. The following primers
were used for Pax2 (Forward- TATGCACTGCAAAGCAGACC
and Reverse- GGGGCAGTCACTCCTGTC) and Gapdh (For-
ward- GCATTGTGGAAGGGCTCATGACC and Reverse-CG-
GCATCGAAGGTGGAAGAGTGG). The parameters for PCR
amplification were 95uC for 10 min followed by 40 cycles of 95uC
for 30 s, 55uC for 30 s and 72uC for30 s. Relative expression of
different mRNA samples for Pax2 and Gapdh was calculated using
the comparative threshold cycle method.
Protein degradation analysis
Pax2 wild type and mutant proteins stability were characterized
by transiently transfecting NIH/3T3 cells with expression vectors
expressing wild type and mutant Pax2 proteins using a modified
method described by Jiang et al [53]. In brief, 24 hrs post-
transfection with equal amounts of wild-type or mutant Pax2
expression vector, cells were treated with cycloheximide (CHX)
(100 mg/ml) (Sigma-Aldrich, St. Louis, MO). Cells were washed
with PBS and lysed with RIPA buffer at 0, 3 and 6 hrs after CHX
treatment. The protein concentrations in the lysates were
determined by BCA method (ThermoFisher Scientific-Pierce,
Rockford, IL). Equal amounts of proteins were resolved in
NuPAGE Novex Bis-Tris gel (4–12%), transferred to PVDF
membrane and probed with Rabbit polyclonal anti-Pax2 (1:250
dilution) and anti-Gapdh (1:500 dilution) primary antibodies.
HRP conjugated anti-rabbit IgG was used as secondary antibody
(1:5000 dilution). SuperSignal West Pico Chemiluminescent
Substrate was used to detect HRP on the blots. The blot was
imaged using Autochemie System (UVP, Upland, CA) and
quantitative analysis of the bands was performed using Labworks
software.
Gel mobility shift assays
COS-7 cells were transiently transfected with CMV-Pax2a
expression construct (wild type or mutant) using FuGENE 6 HD
reagent (Roche-Applied Science, Indianapolis, IN). The cells were
harvested after 48 h and the nuclear extracts were prepared by
using NE-PER nuclear and cytoplasmic extraction kit reagents
(Thermo Scientific-Pierce, Rockford, IL). Gel purified sense and
antisense oligonucleotides representing wild-type or mutant Pax2
DNA binding sites were labeled at the 39 end of DNA strand with
Biotin -11-dUTP (Biotin 39 end DNA labeling kit, Thermo
Scientific-Pierce). The forward wild-type primer was 59TGG-
AATTCAGGAAAAATTGTCACGCATGAGTGGTTAGCTC-
GAGTA-39 and the forward mutant primer was 59TGGAATT-
CAGGAAAAATTTGATACCATGAGTGGTTAGCTCGAGTA -
39, where the underlined sequence represents the portion of
oligonucleotide that was mutated. Gel mobility shift assays were
performed with Biotin -11-dUTP labeled target DNA in 10 mM
Tris-HCl pH 7.5, 100 mM KCl, 0.5 mM DTT, 05% NP-40,
2.5% glycerol and 50 ng/ml poly (dI:dC) and incubated with the
Wt or Mut nuclear extracts in a total volume of 20 ml. After
incubation for 20 minutes, protein-DNA complexes were separat-
ed on a 6% polyacrylamide gel in 0.5 x TBE buffer at 100 V/cm,
transferred onto Nytran membrane and UV cross-linked. Biotin
label was detected by chemiluminescent detection module
(Thermo Scientific-Pierce) that uses luminol substrate for HRP-
conjugated streptavidin. For competition experiments, the nuclear
extracts were pre-incubated with 100 molar excess of unlabeled or
mutant DNA for 10 min. before adding the biotin labeled probe.
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